New research from Mount Sinai School of Medicine has found that the price in New York and New Jersey of the medications most commonly prescribed for patients with diabetes varies widely depending on where you shop. 

A couple of weeks ago we had a new product blurb about Cycloset™, an old drug with a new indication for diabetes. Many of you wrote to ask me for information on how the medication works and where the idea came from. I had our current PharmD candidate, Robert Fredenrich, …

If you are pregnant and your mate complains your frequent snoring is rattling the bedroom windows, you may have bigger problems than an annoyed, sleep-deprived partner

The findings of two 52-week studies show that the investigational ultra rapid acting insulin AFRESA® (insulin human [rDNA origin]) Inhalation Powder combined with basal insulin is comparable to standard of care therapies in controlling post-meal blood sugar levels, and also results in significantly less weight gain and risk of hypoglycemia …

Diabetic patients with poor glycemic control or vascular or neuropathic complications may also suffer from hearing loss. All patients with hemoglobin A1c levels greater than 7% had hearing impairment.

Once-weekly exenatide (EQW) produces superior improvements in glucose control and body weight compared with maximum daily doses of sitagliptin and pioglitazone on background metformin, according to study results presented at the American Diabetes Association (ADA) 69th Scientific Sessions.

Saxagliptin, an investigational dipeptidyl peptidase-4 (DPP4) inhibitor, may offer cardioprevention as a side benefit of diabetes treatment, according to a meta-analysis.

Researchers at the ADA reported that Liraglutide reverses prediabetes indices in most obese patients with existing prediabetes …Full Story

Aleglitazar, a novel dual peroxisome proliferator-activated receptor (PPAR) agonist, is effective for glucose control in Type 2 diabetes and reduces A1c 1.3%.

Lower hemoglobin A1c levels alone don’t appear to increase mortality risk with intensive glucose control, subanalyses of two major diabetes trials revealed. Each 1% lower average HbA1c was associated with a 56% lower relative risk of mortality. Diabetes patients had reduced composite cardiovascular event and mortality rates with intensive glucose …